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ABSTRACT
Introduction: Drug-Drug interactions (DDI) may cause considerable adverse drug reactions and poten-
tially lead to an increased or decreased clinical effect of a given drug and increases the cost of manage-
ment. Cancer patients are at high risk of such DDIs because they commonly receive a high number of 
drugs concomitantly, including other cytotoxic agents, hormonal agents, targeted agents, and supportive 
care agents among medication prescribed to treat comorbidities, especially for elderly patients. The ob-
jective of this study is to evaluate the incidence of comorbidities and the role of clinical pharmacist in 
preventing DDIs in a group of cancer patients.
Materials and Methods: A prospective – observational study was conducted in a multispecialty hospital 
for a period of 8 months among 100 cancer inpatients of oncology department. DDIs were analyzed us-
ing Medscape Drug Interaction checker.
Results: In this study, 65 DDIs were identified from 100 patients. Of all DDIs, 33.85% were major, 60% 
were moderate, and 6.15% were minor DDIs. Clinically significant (55.38 %) DDIs were reported and 
69.44% of those were accepted and modified accordingly. Furthermore, we observed 50.77% of DDIs 
between co administered drugs. Elderly people (48%) have more co-morbidity such as diabetes (30%) 
and hypertension (17.81%).
Conclusion: This study concluded that DDIs are very common in cancer patients, particularly people 
with more co morbidities and using multiple medicines. Clinical pharmacist and physicians must work 
together to extend the practice of preventing DDIs on individual patient management to improve their 
quality of life.
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RESUMEN
Introducción: Las interacciones medicamentosas (DDI) pueden causar reacciones adversas considera-
bles a los medicamentos y, potencialmente, pueden provocar un aumento o disminución del efecto clíni-
co de un medicamento dado y aumentan los costos de administración. Los pacientes con cáncer tienen 
un alto riesgo de tales interacciones porque comúnmente reciben una gran cantidad de medicamentos 
concomitantes, incluidos otros agentes citotóxicos, agentes hormonales, agentes dirigidos y agentes de 
atención de apoyo entre los medicamentos prescritos para tratar las comorbilidades, especialmente en 
pacientes ancianos. El objetivo de este estudio es evaluar la incidencia de comorbilidades y el papel del 
farmacéutico clínico en la prevención de interacciones entre medicamentos en un grupo de pacientes 
con cáncer.
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Materiales y métodos: se realizó un estudio prospectivo - obser-
vacional en un hospital de múltiples especialidades durante un 
período de 8 meses entre 100 pacientes hospitalizados con cáncer 
del departamento de oncología. Las interacciones de fármaco y fár-
maco se analizaron utilizando el comprobador de interacción de 
medicamentos de Medscape.
Resultados: En este estudio, se identificaron 65 interacciones de 
100 pacientes. De todas las interacciones entre medicamentos, 
33,85% fueron mayores, 60% fueron moderadas y 6,15% fueron 
interacciones menores. Se informaron interacciones clínicamente 
significativas (55,38%) y el 69,44% de ellas se aceptaron y modi-
ficaron en consecuencia. Además, observamos el 50,77% de las 
interacciones entre los fármacos coadministrados. Las personas 
mayores (48%) tienen más comorbilidad, como diabetes (30%) e 
hipertensión (17,81%).
Conclusión: este estudio concluyó que las interacciones entre me-
dicamentos son muy comunes en pacientes con cáncer, especial-
mente en personas con más comorbilidades y que usan múltiples 
medicamentos. El farmacéutico clínico y los médicos deben traba-
jar juntos para ampliar la práctica de prevención de interacciones 
entre medicamentos en el manejo individual del paciente para me-
jorar su calidad de vida.
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INTRODUCTION
DDIs more commonly occur when consuming more drugs 
concomitantly, which may also cause considerable adverse 
drug reactions and potentially lead to an increased or de-
creased clinical effect of a given treatment (1- 3). Cancer pa-
tients are at high risk of such DDIs because they commonly 
receive a high number of drugs concomitantly, including 
cytotoxic agents, hormonal agents, targeted agents, and sup-
portive care agents among the medications prescribed to 
treat comorbidities. Particularly, elderly patients have high 
risk to develop DDIs due their physiological changes and 
comorbidies (4). Maximum patients with cancer will develop 
at least one DDIs and it requires medical intervention (5).
Gastro intestinal effects, Central Nervous System depres-
sion and QT prolongation are the most reported DDIs 
among cancer patients. These potential DDIs are needed to 
be noticed by the physician and proper intervention should 
be initiated to improve the health quality of cancer patients. 
This can be achieved by healthy professional interaction be-
tween oncologist, pharmacist, and other health care team 
members (6, 7).
Clinical pharmacists have important role in the cancer 
management by checking DDIs before starting the chemo-
therapy for the successful usage of drugs and improve the 
quality life of the patient. Clinical pharmacist requires skills 
to identify and prevent DDIs which necessitates updating 
the knowledge about DDIs among cancer patients. Hence, 
the present study was aimed to assess the comorbidities, 
DDIs among cancer patients.
MATERIALS AND METHODS (SUBSECC LEVEL 1)
A prospective interventional study was carried out for 
an 8 month period (from August 2016 to March 2017) in 
a Tertiary Care Hospital with Institutional Ethical Com-
mittee approval (Ref no: 12/003). Patients of either gender 
>18 years and diagnosed with cancer were included in the 
study. Patients who were referred to oncology department 
for op consultation, patients who are not willing to partic-
ipate, pregnant and lactating women were excluded from 
the study.
The data were collected from patients’ treatment chart on a 
daily basis and recorded in the drug DDIs’ data collection 
form. Medscape multidrug interaction checker tool was 
used to identify the pattern of DDIs. In Medscape, on en-
tering the drugs one by one, the program lists the possible 
DDIs and categorizes DDIs according to their interaction 
effect. Medscape contains a separate tool for detecting DDIs 
known as the multidrug interaction checker tool and also 
classified the DDIs as major, moderate and minor (8). Major 
DDIs may be life-threatening and/or require medical in-
tervention such as liver failure, abnormal heart rhythms, 
certain types of allergic reactions etc...Moderate or minor 
DDIs may result in exacerbation of the patient’s condition 
and may or may not require an alteration in therapy e.g. 
Nausea, vomiting, headaches and rashes, etc.
The entire drug DDIs were informed to the physician and 
management was provided based on the drug interaction 
tools. Descriptive statistics and chi – square test was used to 
show the significant interaction between the different class 
of drugs. Data analysis was carried out using the Statistical 
Package for Social Studies (SPSS) version 20.
RESULTS (SUBSECTION LEVEL 1)
Among 100 study participants, 65% of patients had drug 
– drug interaction in their prescriptions. In that, 53.85% of 
patients were males and 46.15% were female’s patients. 
Most of the patients were in the age of above 60 years fol-
lowed by 41 – 60 years and less than 40 years. Maximum 
of patients had history of comorbidities and 53.85% of pa-
tients had employment during study period. Diabetes mel-
litus was found to be the most common comorbidity along 
with cancer in both groups with and without DDIs.
The maximum duration of hospital stay was 6 days for can-
cer patients in the study population, even though, the ma-
jority of patients with and without DDIs stayed for 3 days 
to complete their chemotherapy cycles. Demographics of 
study participants were described in Table 1.
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Table 1. Demographic details of study participants
Demographics
No of Patients (n=100)
With DDIs
N=65
Without DDIs
N=35
Gender
Male
35(53.85) 19(54.29)
Female 30(46.15) 16(45.71)
Age
18-40 yrs
10(15.38) 6(17.14)
41-60 yrs 23(35.38) 13(37.14)
61-80 yrs 32(49.23) 16(45.71)
Occupation
Employed
35(53.85) 19(54.29)
Unemployed 28(43.07) 15(42.86)
Student 2(3.08) 1(2.86)
Duration of Hospital stay
2
23(35.38) 12()
3 29(44.62) 15(42.86)
4 9(13.85) 5(14.28)
5 4(6.15) 2(5.71)
6 1(1.54) 1(2.86)
Comorbid conditions
No comorbidity
18(27.69) 9(25.71)
DM 20(30.77) 10(28.57)
hypertension 9(13.85) 4(11.43)
DM & hypertension 3(4.61) 2(5.71)
asthma 2(3.08) 1(2.86)
psychosis 3(4.61) 1(2.86)
Other comorbidities 12(18.46) 6(17.14)
Among 100 patients, 35% had some uncommon type cancer 
like Non-Hodgkin lymphoma, pancreatic cancer...etc. and 
25% had stomach cancer followed by ovarian (10%) and 
breast cancer (9%), which is displayed in Figure 1.
Figure 1. Distribution of patients according to the cancer site.
In multivariate analysis, the dependent variable like age, 
gender, hospital stay, comorbidity, and occupation doesn’t 
affect significantly the occurrence of drug – drug interac-
tion among cancer patients. The multivariate analysis re-
sults are described in Table 2.
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Table 2. Multivariate analysis of dependent variables on occurrence of DDIs
Source Dependent Variables
Type III Sum 
of Square
df Mean Square F Sig.
Drug interaction
Hospital stay .194 1 .194 .233 .630
Age .063 1 .063 .116 .735
Gender .000 1 .000 .002 .967
occupation .000 1 .000 .002 .967
comorbidity .009 1 .009 .044 .834
Table 3 shows the details of drug – drug interaction among 
all cancer patients. Out of 65 drug DDIs, 47.69% had one 
DDI, 30.77% had two types of DDIs and 18.46% had more 
than three type’s DDIs in the treatment chart. Based on the 
severity of DDIs, 60% were moderate, 33.85% were major 
and 6.15% were mild. Clinically, significant DDIs were ob-
served with 36 prescriptions. Out of 65 DDIs, 29 have theo-
retical DDIs which are not observed in cancer patients dur-
ing the study period. All clinically significant DDIs were 
reported to the physician and 25 were accepted and 11 were 
not given priority or accepted.
Also, the study observed 24.62% of DDIs between antican-
cer drugs, 24.62% between anticancer and co-administered 
drugs, and 50.77% of DDIs between co-administered drugs 
as represented in Table 3. Major DDIs were significantly 
(p<0.0001) high in numbers (n=18) between co adminis-
tered drugs which indicates comorbidities increased the 
risk of DDIs. Then, 60% of major DDIs and 28% of moder-
ate DDIs were accepted by the physicians.
Table 3. Details of Drug – Drug Interaction among cancer patients
Details of Drug – Drug DDIs
No of Patients (%)
n= 100(%)
P value
Drug DDIs
Yes
No
72(72)
28(28)
0.000
No of DDIs per patient
One DDIs
Two interaction
Three DDIs
More than three DDIs
31(47.69)
20(30.77)
9(13.85)
12(18.46)
0.000
Severity of DDIs
Minor
Moderate
Major
4(6.15)
39(60)
22(33.85)
0.000
Type of Interaction
Anticancer-Anticancer
Anticancer-Co-administered
Co-administered - Co-administered
16(24.62)
16(24.62)
33(50.77)
0.000
Observed of Interaction
Clinically significant interaction
Non-clinically significant interaction
36(55.38)
29(44.62)
0.000
Reported to physician
Yes
No
36(55.38)
29(44.62)
0.000
Acceptance of DDIs
Yes
No
25(69.44)
11(30.56)
0.000
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Details of Drug – Drug DDIs
No of Patients (%)
n= 100(%)
P value
Acceptance based on severity
Major
Moderate
Minor
15(60)
7(28)
3(12)
0.00
Among anticancer drugs that cause drug interaction, cy-
clophosphamide (n=6) was found be the most common 
interacting drug in cancer patients. With co administered 
drugs, ondansetron (n=5), glimepiride & aceclofenac (n=4), 
and clonidine & levodopa (n=4) have shown more DDIs. 
QT interval prolongation, Hypotension, and was found to 
be the most common consequences of drug – drug interac-
tion among cancer patients. The frequency and percentage 
distribution of clinically significant DDIs are summarized 
in Table 4.
Table 4. Severity of Drug – Drug Interaction based on the drug treatment
Type of interaction
Number of DDIs 
N (%)
Severity of interaction
Minor Moderate Major
Anticancer-Anticancer drugs 16(24.62) 2 14a 0
Anticancer-Co-administered drugs 16(24.62) 1 11a 4
Within Co administered drugs 33(50.77)* 1 14 18*
Figure 2 indicates the management of DDIs among cancer 
patients. Out of a total of 25 accepted drug DDIs, 54.5% 
(n=14) DDIs were managed through dose taper or reduc-
tion, 22.7% (n=6) DDIs were monitored closely, 9% (n=2) 
DDIs were treated by addition of new drug, and 13% (n=3) 
DDIs were managed by drug withdrawal or stoppage. 
During the study period, September ’16 and January’17 got 
highest numbers of DDIs which was described in Figure 3.
Figure 2. Management of accepted Drug –Drug Interactions
Figure 3. Month wise report of Drug – Drug Interactions
DISCUSSION
Cancer patients are more likely to develop drug – drug 
interaction due to treatment with multiple medication si-
multaneously. This study assessed the various comorbid-
ities, DDIs and their management among cancer patients. 
In this population, male cancer patients were dominant 
compared to female patients, which is similar to previous 
reports shown by Van Leeuwen RW et al., which found 
high prevalence of cancer in male patients (9). Age is an 
important factor to increase the chance of drug interaction 
due to multiple medications for comorbid conditions as 
well as age-related decline in hepatic and renal functions 
which reduces patient ability to metabolize and clear drugs 
(10,11). This study results proved that advanced age group 
(>60 years) have more drug interaction than younger age. 
Furthermore, comorbid conditions associated with can-
cer might add number of medications to the drug chart of 
cancer patients. Our study results indicates that 72.31% of 
study participants had comorbidities and another study 
found that the median number comorbidities per patient 
was one and this means that all cancer patients suffered 
from at least one comorbidity. Stomach cancer was found 
to be the most common type of cancer in this population, 
which is further supported by earlier studies and suggests 
a high prevalence of stomach cancer among male popula-
tion. But, contradictory to our study another study report-
ed a high prevalence of cervical cancer in women (12).
The number of drug interaction per prescription in the 
present study was found to be the range of 1 – 5 and pre-
scription with one drug interaction was highly significant 
(p<0.0001). But, former studies on patient care revealed 
that the increase in DDIs in the prescriptions occurs when 
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number of items per prescription increased with more than 
four drugs, thereby, also in the number of potentially inter-
acting drug combinations per patient. Also, they found that 
a positive correlation exists between the incidence of DDIs 
and number of drugs prescribed. Generally, patients have 
several concurrent diseases and, consequently, the number 
of drugs used to treat them is greater. The greater the num-
bers of drugs have higher the possibility of DDIs (13).
Based on the severity, this study found that maximum DDIs 
were moderate and major; few DDIs were minor. Similar-
ly, a study done by the team from a south Indian tertiary 
care teaching hospital in Chennai, Tamilnadu, reported that 
more than a 50% of cancer patients may be at risk of poten-
tially moderate DDIs (14).
This study results shows that a high prevalence of mod-
erate DDIs in cancer patients. But, anticancer drugs were 
not the primary source for drug interaction. The majority of 
DDIs are between different classes of co administered med-
ications received for co-morbidities and cancer supportive 
care were more likely to be involved. It indicates that co ad-
ministered drug have an impact or increase the occurrence 
of drug interaction in cancer patients.
In the same way, another study supported that the chemo-
therapeutic agents have lesser number of drug interaction 
compared to non-anticancer agents. Like other study re-
ports, this study also confirms that cancer patients those 
have used drugs concomitantly to treat comorbidities have 
been identified as a risk factor for the occurrence major type 
of DDIs (15).
In 2008, a similar study conducted and reported by Wong 
CM et al, showed 21.7% clinically significant DDIs from the 
184 DDIs that were identified (16). The effect of drug inter-
action, which is described in database, and was clinically 
observed on daily basis of patient life, is known as clini-
cally significant interaction. In this study, more than half of 
the DDIs were found to be clinically significant during the 
study period. The remaining DDIs that were not clinically 
observed with patients are called as theoretical DDIs. All 
significant DDIs were reported to the concern of physician 
for further management of drug interaction. In that, a small 
number of DDIs were not accepted due to non-serious reac-
tion from the physician point of view.
Mostly, the accepted DDIs were managed with dose adjust-
ment and few of them needed close monitoring of patients. 
Leape et al in 1999 observed that pharmacists often identi-
fied potential drug related DDIs and suggested dose cor-
rections which was not accepted because the physician be-
lieved that the benefits of continue treatment outweighed 
the risk of DDIs (17).
Another finding in this study includes QT interval prolon-
gation. This was frequently observed as an adverse out-
come due to DDIs and cyclophosphamide was the most 
frequent anticancer drug involved in this DDIs. Equally, 
many other studies concluded that QT interval prolonga-
tion was found to be the most common DDI outcome in 
cancer patients (18). On the other hand, a conflicting report 
by Mouzon A et.al suggested that Cisplatin was the most 
common anticancer drug responsible for DDIs because it 
was prescribed frequently in their study population (19). All 
the patients with DDIs were well managed and got recover 
from adverse effects except those need monitoring closely. 
Even though not accepted, the qualities of life of patients 
were not affected considerably because of DDIs was not 
life-threatening in this study.
CONCLUSION
This study concludes that DDIs are very common in cancer 
patients, particularly in people with more co morbidities 
and using multiple medicines. Clinical pharmacists and 
physicians must work together to extend the practice of 
preventing DDIs on individual patient management to im-
prove their quality of life.
Professional insight into the clinical consequences of DIs in 
cancer patients is not well known and further study need to 
be investigated. Physicians and clinical pharmacists must 
collaborate to extend the practice of identify DIs upon drug 
prescription, which includes the knowledge, awareness, 
and attentiveness during the use of anticancer drugs and 
supportive or co administered drugs.
There is an imperative need to tackle these DDIs in an or-
ganized and efficient manner and to provide this informa-
tion to the healthcare professionals during patient care and 
it may improve the quality of health care provided to can-
cer patients. This can be achieved probably through specific 
teaching in oncology and could be put into practice to re-
duce medication related problems and optimize therapeu-
tic treatments.
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